文献速递乳腺癌放疗

乳腺癌辅助放疗期间局部强效激素治疗的晚期皮肤效应

Late cutaneous effects of a local potent steroid during adjuvant radiotherapy for breast cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2017-10-07

该随访研究纳入60例(32例强效激素乳膏组 vs 28例保湿剂对照组)曾参与2009—2010年随机研究的乳腺癌辅助体外放疗患者,于2016年评估晚期皮肤毒性。结果表明预防性皮质激素治疗未增加晚期皮肤毒性,也未导致皮肤萎缩,但样本量小且存在假阳性风险。

要点

  • 平均随访6年,客观仪器测量未见皮肤干燥、颜色、色素沉着或厚度显著差异。
  • RTOG评分显示保湿剂组晚期皮肤问题的比值比为3.2(95%CI:1.0-10.1)。
  • 预防性皮质激素未导致皮肤萎缩,但研究样本量小、存在假阳性风险。

核心结论

  • 乳腺癌辅助体外放疗期间预防性使用皮质激素以减轻放射性皮炎,未增加晚期皮肤毒性,也未导致皮肤萎缩。

研究设计与样本

  • 随访研究,纳入2009—2010年一项随机研究的60例患者,32例强效皮质激素乳膏组、28例保湿剂对照组,于2016年随访评估。

主要发现

  • 60例中均未观察到皮肤萎缩;客观仪器测量在平均6年随访中未发现皮肤干燥、颜色、色素沉着或皮肤厚度的显著差异。
  • 基于RTOG评分的临床评估显示,保湿剂组相比皮质激素组出现晚期皮肤问题的比值比为3.2(95%CI:1.0-10.1)。
  • 患者报告轻微美容性皮肤后遗症,7例出现毛细血管扩张并造成美容困扰。

关键数值与推荐

  • 晚期皮肤评估采用Late Radiation Morbidity Scoring Scheme(RTOG);皮肤干燥、颜色和厚度使用非侵入性仪器客观测量,并比较患侧与未治疗侧乳房。

临床怎么用

  • 在乳腺癌辅助体外放疗期间使用局部强效皮质激素预防放射性皮炎,随访未见晚期皮肤毒性增加,可作为安全性参考。

局限性

  • 样本量小,且存在假阳性发现的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate whether treatment with a local potent corticosteroid during adjuvant external radiotherapy (ERT) of breast cancer is associated with late skin toxicity. MATERIAL AND METHODS: Sixty patients (32 treated with potent corticoid cream versus 28 controls treated with moisturizer) who had been included in a randomized study on prophylactic local corticosteroid treatment under adjuvant ERT in 2009 and 2010 were subjected to a follow-up study in 2016.Assessments of skin texture were registered according to the Late Radiation Morbidity Scoring Scheme (RTOG). Dryness, skin colour and skin thickness were objectively measured using non-invasive instruments. The patients were assessed for differences between their treated and untreated breasts. RESULTS: Skin atrophy was not noticed in any of the 60 patients. Objective instrumental measurements did not reveal any significant differences in skin dryness, colour, pigmentation or skin thickness over the average follow-up time of six years. Clinical assessment based on the RTOG scoring system revealed that the odds ratio of having late skin problems in patients treated with moisturizer compared to patients treated with corticosteroid was 3.2 (95% CI: 1.0-10.1).Patients reported minor cosmetic dermatological sequelae. Seven patients developed telangiectasia, which caused cosmetic inconvenience. CONCLUSION: In this study, prophylactic corticosteroid treatment to ameliorate radiation dermatitis during adjuvant ERT of breast cancer was not associated with an increase in late skin toxicity nor did it result in skin atrophy. This study is limited by its small sample size, and the risk for false positive findings.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ulff E, Maroti M, Serup J, et al. Late cutaneous effects of a local potent steroid during adjuvant radiotherapy for breast cancer. Clin Transl Radiat Oncol. 2017. PMID: 29594223. doi:10.1016/j.ctro.2017.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。